At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 202 enrolled
Drug / intervention
imatinib mesylate +1 moredrug
Likely dose
imatinib mesylate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
In Brief
A Phase 3 clinical trial evaluating imatinib mesylate and Placebo for Pulmonary Arterial Hypertension. Completed, enrolled 202 participants across 95 sites in 14 countries.
Detailed Summary
A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesAustria, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, South Korea, Spain, Sweden, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartSep 2009
Primary CompletionMay 2011
TodayJul 2026
First PostedMay 15, 2009
Enrollment StartSep 1, 2009
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.1 years ago
Interventions
imatinib mesylatedrug
Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
Placebodrug
Placebo to imatinib 100 mg film coated tablets